Acute treatment with relaxin attenuates the injury/dysfunction induced by renal ischemia/reperfusion injury.

Abstract

Although preclinical and clinical studies have demonstrated that relaxin (RLX) ameliorates impaired renal function by exerting antifibrotic and regenerative effects, its role in renal ischemia/reperfusion (I/R) injury has never been investigated. Using a well-known rat model of 1 h bilateral renal artery occlusion followed by 6 h reperfusion, we investigated the effects of human recombinant RLX (5 microg /Kg e.v.) given both at the beginning and after 3 h reperfusion. Serum and urinary indicators of renal injury and dysfunction were measured. Interestingly, administration of the exogenous RLX attenuated all markers of renal injury and dysfunction caused by I/R. Overall, we document here, for the first time, that RLX protects against I/R-induced renal injury and dysfunction. The results of this study offer good perspectives for the clinical potential of RLX in the medical treatment of renal diseases.

• Authors: Massimo Collino, Mara Rogazzoi, Alessandro Pini, Elisa Benetti, Arianna Carolina Rosa, Roberto Fantozzi, Daniele Bani, Emanuela Masini
• Journal: Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia (Ital J Anat Embryol) Vol. 118 Issue 1 Suppl Pg. 74-6 ( 2013) ISSN: 1122-6714 [Print] Italy
• PMID: 24640578 (Publication Type: Journal Article)

Chemical References

• RLN1 protein, human
• Relaxin

Topics

• Acute Kidney Injury (drug therapy)
• Animals
• Disease Models, Animal
• Humans
• Male
• Oxidative Stress (drug effects)
• Rats
• Rats, Wistar
• Relaxin (pharmacology)
• Reperfusion Injury (drug therapy)